American Society of Hirudotherapy

Management of Life-Threatening Bleeding in Patients With Mechanical Heart Valves.

Review published in Cureus (2021)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewClinical TrialsDrug DevelopmentHuda et al. · Cureus, 2021

Abstract

Valvular heart disease is common in the United States, with a number of patients undergoing valve replacement procedures every year. The two types of valve prostheses include mechanical and bioprosthetic valves. Mechanical heart valves require lifelong anticoagulation with vitamin K antagonists like warfarin. The clinicians are often faced with the dilemma of major bleeding episodes such as intracranial hemorrhage or gastrointestinal bleeding in these patients. The management includes reversing warfarin-induced coagulopathy with vitamin K supplementation, fresh frozen plasma, or prothrombin complex concentrate (PCC), with PCC being the treatment of choice. With regard to the safe resumption of anticoagulation, guidelines are silent, and data is limited to case reports/series. This article reviews the present literature for the management of bleeding in patients with mechanical heart valves and the safe duration for holding off anticoagulation with minimal risk of valve thrombosis/thromboembolism.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview

Summary

Valvular heart disease is common in the United States, with a number of patients undergoing valve replacement procedures every year. The two types of valve prostheses include mechanical and bioprosthetic valves.

Why This Matters for Hirudotherapy

This review addresses management of life-threatening bleeding in patients with mechanical heart valves requiring chronic warfarin anticoagulation, discussing reversal strategies including vitamin K, fresh frozen plasma, and prothrombin complex concentrate, as well as the safe timing for resuming anticoagulation after major hemorrhage. The relevance to ASH's domain is minimal and indirect: while leech-derived hirudin is an anticoagulant and the article concerns anticoagulation management, no leeches, hirudin products, or hirudotherapy are discussed. The review focuses on reversing pharmacological anticoagulation and balancing bleeding versus thrombosis risk in mechanical valve patients, with no demonstrated connection to therapeutic leeching or the leech secretome.

Citation

Management of Life-Threatening Bleeding in Patients With Mechanical Heart Valves.

Huda et al. · Cureus, 2021

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.